INDIA – Dr. Reddy’s Laboratories has ventured into the trade generics business in India with the launch of its new dedicated division ‘RGenX’.

Dr. Reddy’s Laboratories has forayed into India’s trade generics segments with RGenX to increase patient access to a wide range of products at affordable prices across all geographic areas.

The global pharmaceutical company will be rolling out its new business across cities and towns in India, aligning with the company’s goal of reaching over 1.5 billion patients by 2030.

In an official statement, M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s Laboratories, underscored: “India is a key focus market for us. We are exploring strategic collaborations in India, and investing in innovative healthcare spaces that we see as future growth drivers.”

The company offers a wide portfolio of products and services through its three businesses: Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products.

Dr. Reddy’s Laboratories will work closely with its channel partners to improve the availability and accessibility of its exclusive range of medical products for consumers in rural regions and urban areas.

Through its new division, Dr. Reddy’s Laboratories aims to enhance new patient access, reduce healthcare costs and improve patient health outcomes.

“This foray into trade generics will add to our reach and depth by making high-quality medicines of Dr. Reddy’s
accessible to more patients around the country in keeping with our purpose of ‘Good Health Can’t Wait’,” said M.V. Ramana.

This market entry comes after Dr. Reddy’s tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

The successful outcome of the Phase I study used an intravenous formulation to evaluate the pharmacokinetic equivalence, safety, and immunogenicity of Dr. Reddy’s tocilizumab biosimilar candidate in comparison to reference products.

This positive result underscores the company’s commitment to developing high-quality biosimilars and reinforces the potential of DRL_RI as a safe and effective treatment option for patients across the globe.

Moreover, Dr. Reddy’s Laboratories will continue to pursue further growth in India in line with the company’s strategy to grow its brands organically combined with acquisitions that are a strategic fit and divestment of non-core brands.

“We continue to strengthen our branded generics business in India by growing brands, new product launches, productivity enhancement through digital and analytics, and select strategic acquisitions,” outlined M.V. Ramana.

In another development, Dr. Reddy’s Laboratories agreed to sell certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited in a deal worth Rs. 275 crores (US$33.2 million).

The pharma giant took a deeper dive into healthcare in February by taking over the generic prescription product portfolio of Mayne Pharma in the United States for up to US$150 million.

Dr. Reddy’s Laboratories also acquired the domestic sale rights for the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd earlier this year.

According to GlobalData, a data and analytics company, the differentiated approach of Dr. Reddy’s Laboratories to its product offerings is a key part of its growth strategy in India.

These strategic deals will build upon the ongoing efforts of the Hyderabad-based company to accelerate and expand access to quality, affordable medications for patients.

“Expanding into a new segment of the pharmaceutical manufacturing industry is a continuation of our effort to build a well-rounded business in India,” underscored Ramana.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.